Nicotinamide Adenine Dinucleotide — Longevity Coenzyme Precursors
NAD+ is a coenzyme essential to over 500 enzymatic reactions, central to energy metabolism, DNA repair, and the sirtuin longevity pathways. Levels decline 40–50% between ages 20 and 60. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are the two primary NAD+ precursors under active clinical investigation — both converting to NAD+ through distinct enzymatic pathways. Among the most researched and discussed longevity compounds in existence.
01 — Research Summary
NAD+ precursor research has exploded over the past decade, moving from animal studies to a substantial human clinical trial dataset. The field is still maturing — some early promises have been tempered by the complexity of human metabolism — but the mechanistic foundation and safety profile are among the strongest in longevity research.
NMN supplementation significantly raises blood NAD+ in humans. A key 2022 human RCT demonstrated that oral NMN supplementation at 300–600mg/day significantly increased blood NAD+ levels, confirming effective conversion in humans — settling a previous debate about whether oral NMN was absorbed intact or degraded before conversion.
Improved muscle endurance and oxygen utilisation. A randomised trial in amateur runners over 60 found 12 weeks of NMN supplementation improved aerobic capacity and muscle endurance — providing the first human evidence linking NAD+ restoration to measurable physical performance in aging.
Consistent NAD+ elevation with excellent safety profile. Multiple RCTs of nicotinamide riboside across doses from 250–2000mg/day confirmed effective NAD+ elevation with no serious adverse events — establishing the strong safety profile that has encouraged widespread adoption as a supplement.
IV NAD+ shows rapid metabolic improvements. Clinical data on intravenous NAD+ administration demonstrates rapid restoration of intracellular NAD+ alongside meaningful improvements in metabolic markers, insulin sensitivity, and subjective fatigue — though the IV route remains primarily clinical.
02 — Mechanism of Action
NAD+ sits at the centre of multiple longevity and metabolic pathways simultaneously. Understanding why it matters requires understanding the biological systems it enables.
NAD+ is the essential cofactor for sirtuin enzymes — the so-called 'longevity genes' activated by caloric restriction. Sirtuins regulate gene expression, DNA repair, mitochondrial biogenesis, and inflammation. Declining NAD+ with age directly impairs sirtuin function across all seven family members.
Poly (ADP-ribose) polymerase (PARP) enzymes consume NAD+ to repair DNA strand breaks. As DNA damage accumulates with age, PARP activity increases, consuming more NAD+ — potentially creating a vicious cycle that depletes the NAD+ needed for sirtuin function. NAD+ restoration interrupts this cycle.
NAD+ is the primary electron carrier in the mitochondrial electron transport chain. In its reduced form (NADH), it transfers electrons to generate ATP. Declining NAD+ directly reduces mitochondrial efficiency and cellular energy production — experienced as fatigue and reduced exercise capacity.
NMN converts to NAD+ through a single enzymatic step (NMNAT enzymes). NR first converts to NMN, then to NAD+. Both pathways are active in humans, though tissue-specific enzyme expression means different precursors may be more effective in different tissues — an active research question.
A key mechanism underlying age-related NAD+ decline is increased activity of CD38 — an enzyme that degrades NAD+. CD38 activity increases significantly with age and inflammation, consuming NAD+ faster than it can be regenerated. Some interventions target CD38 inhibition alongside NAD+ supplementation.
The honest answer is: we don't yet know with certainty for most use cases. NMN has shown more consistent results in human trials for physical performance. NR has a longer safety dataset and more completed human trials overall. IV NAD+ bypasses absorption questions entirely but requires clinical access. Most practitioners consider them broadly comparable for general NAD+ restoration, with individual response being the practical determinant.
03 — Dosing Protocols
Oral NAD+ precursors are well-tolerated at a wide range of doses. The optimal dose remains an active research question — higher isn't necessarily better given the metabolic complexity of NAD+ regulation.
| Protocol | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| NMN — standard | 300–500 mg | Daily, morning | Ongoing | Most studied range. Take with food. Some evidence for morning dosing aligning with circadian NAD+ rhythms. |
| NMN — higher dose | 750–1000 mg | Daily, split | Ongoing | Higher doses used in community longevity protocols. Some trials use up to 1200mg with good tolerability. |
| NR — standard | 250–500 mg | Daily | Ongoing | Well-studied dose range across multiple RCTs. Most safety data exists here. |
| NAD+ IV | 500–1000 mg | 1–2x per week | 6–12 week courses | Clinical administration. Rapid results, bypass absorption concerns. Rate of infusion matters — too fast causes flushing and discomfort. |
Oral NAD+ precursors have an excellent safety profile at standard doses. High-dose niacin (a less direct precursor) can cause flushing — NMN and NR do not typically cause this. Theoretical concern exists around NAD+ feeding cancer cells in active malignancy — a precaution worth discussing with oncologists. Some users report insomnia with high evening doses; morning dosing is preferred.
04 — Community Experiences
NAD+ has perhaps the most mainstream of any compound on this site — discussed across r/longevity, r/Supplements, r/biohacking, and increasingly in mainstream media following coverage from researchers like David Sinclair (Harvard) and Peter Attia. The community is large, diverse, and ranges from casual supplement users to sophisticated longevity protocol designers. Key debates: NMN vs NR, optimal dose, morning vs evening, and whether oral supplementation achieves meaningful intracellular NAD+ restoration in older tissues.
These are user-reported experiences from public forums. Not endorsed by Whats That Peptide and should not be interpreted as clinical evidence. Individual results vary. Always consult a healthcare professional.
"NAD+ blood levels up 60% from baseline. Energy better. Sleep quality improved significantly. Can't attribute everything to NMN since I changed other things too. But I'll keep taking it — the mechanistic case is compelling even if the subjective effects are subtle..."
"Tried both rigorously. NMN felt slightly more energising. NR felt cleaner with less GI sensitivity. Both raised my blood NAD+ meaningfully. I now take NMN in the morning and NR occasionally as a cheaper alternative. The difference is smaller than the marketing suggests..."
"The animal data is extraordinary. The human data is promising but more modest. The mechanistic case is solid. My practical take: it's worth taking if you can afford it, but don't expect dramatic subjective effects — think of it as maintenance, not enhancement..."
"The difference between oral NMN and IV NAD+ is significant. The IV produces an almost immediate clarity and energy that oral doesn't match. Expensive and inconvenient but for serious longevity protocols I think it's worth the occasional course..."